SCHEMBL5369742

SCHEMBL5369742

Cc1c(O)ccc(C=C2C(=O)Nc3ccc(Br)c(C)c32)c1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K7 O43318 1/20 0.45
TAB1 Q15750 1/20 0.45
MAP1LC3B Q9GZQ8 3/20 0.39
RAF1 P04049 6/20 0.38
LRRK2 Q5S007 3/20 0.38
PLK4 O00444 3/20 0.38
PLK1 P53350 2/20 0.37
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
EGFR P00533 1/20 0.37
NTRK1 P04629 1/20 0.37
ARAF P10398 1/20 0.37
PIM1 P11309 1/20 0.37
BRAF P15056 1/20 0.37
CSNK2A1 P68400 1/20 0.37
PIM3 Q86V86 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369354 0.93 MAP3K7 (0.54) MAP3K7TAB1MAP1LC3BRAF1LRRK2
SCHEMBL7136654 0.86 MAP3K7 (0.44) MAP3K7TAB1MAP1LC3BRAF1LRRK2
SCHEMBL5363813 0.84 PLK4 (0.47) MAP1LC3BRAF1LRRK2PLK4PLK1
SCHEMBL5377075 0.82 NPC1 (0.42) MAP3K7TAB1RAF1LRRK2PLK4
SCHEMBL5365128 0.82 LRRK2 (0.51) RAF1LRRK2PSEN1PSEN2APH1B
SCHEMBL7139752 0.81 MAP3K7 (0.39) MAP3K7TAB1MAP1LC3BRAF1LRRK2
SCHEMBL5369739 0.81 MAP1LC3B (0.43) MAP1LC3BRAF1LRRK2PLK4PLK1
SCHEMBL7136800 0.81 MAP1LC3B (0.56) MAP1LC3BRAF1LRRK2PLK4PLK1
SCHEMBL5367152 0.81 LRRK2 (0.48) MAP1LC3BRAF1LRRK2PLK4PLK1
SCHEMBL5357671 0.80 LRRK2 (0.51) LRRK2NTRK1MAPTMDM2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MAP3K7 184/4885TAB1 756/4885MAP1LC3B 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.